Endostaler Kallus
6. Literaturverzeichnis
1 Einhorn TA, Lane JM. Significant advances have been made in the way surgeons treat fractures [editorial]. Clin Orthop 1998;2-3.
2 Coles CP, Gross M. Closed tibial shaft fractures: management and treatment complications. A review of the prospective literature.
Can J Surg 2000;43(4):256-62.
3 McKibbin B. The biology of fracture healing in long bones.
J Bone Joint Surg 1978;60-B(2):150-162.
4 Einhorn TA. The cell and molecular biology of fracture healing.
Clin Orthop 1998;355:7-21.
5 Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res 1999;14:1805-15.
6 Frost HM. The biology of fracture healing. An overview for clinicans. Part I.
Clin Orthop 1989;248:283-93.
7 Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury Int J Care Injured 2005;36:1392-1404.
8 Frost HM. Bone dynamics in metabolic bone disease.
J Bone Joint Surg Am 1966;48(6):1192-203.
9 Einhorn TA. Current concepts review. Enhancement of fracture healing.
J Bone Joint Surg Am1995;77:940-956.
10 Runkel M, Rommes PM. Pseudarthrosen. Unfallchirurg 2000;103:51-63.
11 Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC. The expression of cytokine activity by fracture callus. J Bone Miner Res 1995;10:1272-81.
12 Schmidmaier G, Wildemann B, Cromme F, Kandziora F, Haas NP, Raschke M.
BMP-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment. Bone 2002;6:618-22.
13 Schmidmaier G, Wildemann B, Bail H, et al. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone 2001;28:341-350.
14 Schmidmaier G, Wildemann B, Gäbelein T, et al. Synergistic effect of IGF-I and TGF-1 on fracture haeling in rats - Single versus combined application of IGF-I and TGF-β1. Acta Orthop.Scand 2003;74:604-10.
15 Schmidmaier G, Wildemann B, Lucke M, et al. Insulin like growth factor-I (IGF-I) and transforming growth factor-ß1 (TGF-ß1) have synergistic effects on fracture healing in rats. Trans Orthop Res Soc 2001;47:102.
16 Schmidmaier G, Wildemann B, Lübberstedt M, Haas NP, Raschke M. IGF-I and TGF-beta 1 incorporated in a poly(D,L-lactide) implant coating stimulates osteoblast differentiation and collagen-1 production but reduces osteoblast proliferation in cell culture. J Biomed Mater Res Applied Biomat 2003;65b:157- 62.
Literaturverzeichnis 17 Schmidmaier G, Wildemann B, Ostapowicz D, et al. Long term effects of local
growth factor (IGF-I AND TGF-1) treatment on fracture healing - A safety study for using growth factors-. J Orthop Res 2004;22(3):514-9.
18 Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation:
molecular clones and activities. Science 1988;242:1528-34.
19 Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9.
20 Urist MR, Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979;76:1828-32.
21 Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches.
Bone 1998;22:591-603.
22 Wang EA, Rosen V, D'Alessandro JS, et al. Recombinant human bone
morphogenetic protein induces bone formation.
Proc Natl Acad Sci 1990;87(6):2220-4.
23 Einhorn TA, Majeska RJ, Mohaideen A, et al. A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair.
J.Bone Joint Surg Am 2003;85-A(8):1425-35.
24 Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing.
J Bone Miner Res 2002;17:513-20.
25 Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002;143:1545-53.
26 Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients.
J Bone Joint Surg Am 2002;84-A:2123-34.
27 Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
N Engl J Med 1990;322:802–9.
28 Lane N, Sanchez S, Modin G, Genant H, Pierini E, Arnaud C. Parathyroid hormone treatment can reverse cortiscosteroidinduced osteoporosis.
J Clin Invest 1998;102:1627–33.
29 Hodsman AB, Fraher LJ. Biochemical responses to sequential human parathyroid hormone (1–38) and calcitonin in osteoporotic patients. Bone Miner 1990;9:137–52.
30 Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
31 Barbehenn EK, Lurie P, Wolfe SM. Osteosarcoma risk in rats using PTH 1-34.
Trends Endocrinol Metab 2001;12:383.
32 Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946–9.
Literaturverzeichnis
78 33 Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study.
Ann Intern Med 1971;74:1-12.
34 Endo A, Kuroda M, Tsujita Y. ML-236 A, ML-236B, and ML- 236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum.
J Antibiot (Japan) 1976;29:1346–8.
35 Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosk1980;35:259-66.
36 Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med 1990;323:1289-98.
37 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet 1994;344: 1383–9.
38 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterollevels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001–9.
39 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
N Engl J Med 1998;339:1349-57.
40 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
41 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.
42 Rychlik R, Nordt TK, Nelles S. Statins-Innovative Drugs versus Generic Drugs. A systematic literature search on Atorvastatin and Simvastatin. Gesundh ökon Qual mang 2003;8:307-313.
43 Schwabe U, Paffrath D (Hrsg.) Arzneiverordnungs-Report 2007, Heidelberg:
Springer-Verlag 2008;9:985.
44 Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Research1980;21:507–17.
45 Horiuchi N, Maeda T. Statins and bone metabolism. Review article.
Oral Dis 2006;12:85-101.
46 LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–6.
47 Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;271:688–92.
48 Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
Literaturverzeichnis 49 Lacoste L, Lam JY, Hung J, Letchacovski G,Solymoss CB, Waters D.
Hyperlipidemia and coronary disease. Correction of the increased thrombogenetic potential with cholesterol reduction. Circulation 1995;92:3172-7.
50 Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
51 Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering – are they clinically relevant? Eur Heart J 2003;24:225-48.
52 Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer`s disease β-Amyloid peptides Aβ42 and Aβ40 in vitro and in vivo.
Proc Natl Acad Sci USA 2001;98:5856-61.
53 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
54 Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents.
Arterioscler Thromb Vasc Biol 2001;21:1636–41.
55 Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 2002;17:2004-8.
56 Gutierrez G, Lalka D, Garrett I, Rossini G, Mundy G. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int 2006;17:1033-42.
57 Wong RWK, Rabie ABM. Statin collagengrafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofacial Surg 2003;41:244-8.
58 Garrett IR, Gutierrez GE, Rossini G, et al. Locally Delivered Lovastatin Nanoparticles Enhance Fracture Healing in Rats.
J Orthop Res 2007;25(10):1351-7.
59 Skoglund B, Aspenberg P. Locally applied simvastatin improves fracture healing in mice. BMC Musculoskelet Disord 2007;27;8:98.
60 Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M.
Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J Biomed Mater Res, Applied Biomat 2001;58(4):449-55.
61 Schmidmaier et al EJT 2004. PDF siehe homepage.
62 Garrett IR, Gutierrez G, Mundy GR. Statins and bone formatin.
Curr .Pharm Design 2001;7:715-36.
63 Maeda T, Matsunuma A, Kawane T, et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells.
Biochem Biophys Res Commun 2001;280:874–7.
64 Phillips BW, Belmonte N, Vernochet C, et al. Compactin enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res Commun 2001;284:478-84.
65 Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases
cancellous bone mass and compressive strength.
Calcif Tissue Int 2001;69:299–304.
Literaturverzeichnis
80 66 Oxlund H, Andreassen TT. Simvastatin treatment partially prevents
ovariectomy-induced bone loss while increasing cortical bone formation. Bone 2004;34:609–18.
67 Ayukawa Y, Okamura A, Koyano K. Simvastatin promotes osteogenesis around titanium implants. Clin Oral Implants Res 2004;15:346–50.
68 Von Stechow D, Fish S, Yahalom D, et al. Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord 2003;4:8.
69 Bauer DC. HMG-CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003;14:273–82.
70 Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146–52.
71 Gonyeau MJ. Statins and osteoporosis: a clinical review.
Pharmacotherapy 2005;25:228–43.
72 Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211–6.
73 Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205–10.
74 Van Staa TP, Wegman S, De Vries F, et al. Use of statins and risk of fractures.
JAMA 2001;285:1850–5.
75 LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 2003;139:97–104.
76 Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture: 4S Study group.
JAMA 2000;284:1921–2.
77 Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001;357:509–12.
78 Nguyen ND, Wang CY, Eisman JA, Nguyen TV. On the association between statin and fracture: A Bayesian consideration. Bone 2007;40:813-20.
79 Toh S, Hernández-Dıáz S. Statins and fracture risk. A systematic review.
Pharmacoepidemiol Drug Saf 2007;6:627-40.
80 Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355:2218–9.
81 Cauley JA, Jackson R, Pettinger M, et al. Statin use and bone mineral density (BMD) in older women: the Women’s Health Initiative Observational Study (WHI-OS). J. Bone Miner. Res. 2000;15 (Suppl.):1068.
82 Montagnani A, Gonnelli S, Cepollaro C, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003;32:427–33.
83 Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density and fracture risk: Geelong Osteoporosis Study.
Arch Intern Med 2002;162:537–40.
Literaturverzeichnis 84 Schoofs MW, Sturkenboom MC, van der Klift M, Hofmann A, Pols HA, Stricker BH.
HMG-CoA reductase inhibitors and the risk of vertebral fracture.
J Bone Miner Res 2004;19:1525–30.
85 Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L.
Hip fracture risk in statin users-a population-based Danish case-control study.
Osteoporos Int 2004;15:452–8.
86 Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3methyglutary-coenzyme A reductase. Am J Cardiol 1994;73:3D–11D.
87 Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.
Trends Pharmacol Sci 1998;19:26-37.
88 Wang JW, Xu SW, Yang DS, Lv RK. Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int 2007;18(12):1641-50.
89 Nyan M, Sato D, Oda M, et al. Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect.
J Pharmacol Sci 2007;104:384-6.
90 Thylin MR, McConnell JC, Schmid MJ, et al. Effects of statin gels on murine calvarial bone. J Periodontol 2002;73:1141–8.
91 Gutierrez GE, Edwards JR, Garrett IR, et al. Transdermal lovastatin enhances fracture repair in rats.J Bone Miner Res. 2008;23(11):1722-30.
92 Endo A. The discovery and development of HMG-CoA reductase inhibitors.
J Lipid Res. 1992;33(11):1569-82.
93 Sorensen T S, Sorensen AI, Merser S. Rapid release of gentamicin from collagen sponge. In vitro comparison with plastic beads. Acta Orthop Scand 1990;61:353-6.
94 Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-30s.
Abkürzungsverzeichnis
82